Conference Coverage

SGLT inhibition back on track in phase 3 type T1DM trial

Publish date: October 18, 2017

 

AT EASD 2017

Pages

Recommended Reading

No increased overall cardiovascular risk seen with exenatide use
MDedge Cardiology
Alirocumab’s ODYSSEY continues: Efficacy unaffected by insulin, beats fenofibrate
MDedge Cardiology
Empagliflozin’s effects independent of CVD risk factors
MDedge Cardiology
FDA approves first non–finger-stick glucose monitoring system
MDedge Cardiology
Many years on metformin linked to anemia risk
MDedge Cardiology
Fasting glucose fluctuations, severe hypoglycemia up T2DM death risk
MDedge Cardiology
Intensified approach reduces long-term heart failure risk in T2DM
MDedge Cardiology
Triple therapy for type 2 diabetes goes beyond glucose control
MDedge Cardiology
Oral semaglutide achieves outcomes similar to those of subcutaneous semaglutide
MDedge Cardiology
Vitality predicts T2DM major cardiovascular event risk
MDedge Cardiology